Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes

Cancer Genetics and Cytogenetics

Volumn 175, Issue 1, 2007, Pages 65.e1-65.e5

  Sáez, Borja ^a,b   Martín Subero, José I ^a   Lahortiga, Idoya ^c   Largo, Cristina ^d   Larrayoz, María J ^b   Odero, María D ^a,c   Prosper, Felipe ^e   Cigudosa, Juan C ^d   Siebert, Reiner ^a   Calasanz, María J ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d Structural Biology and Biocomputing Programme   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; ARTICLE; CCND1 GENE; CONTROLLED STUDY; FGFR3 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE ACTIVATION; GENE FUSION; GENE LOCUS; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; LEUKEMIA CELL LINE; MULTIPLE MYELOMA; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; PROTO ONCOGENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; UPREGULATION; CELL LINE; CHROMOSOME BANDING PATTERN; CHROMOSOME PAINTING; GENE EXPRESSION REGULATION; GENETICS; KARYOTYPING; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CYCLIN D; CYCLINE; FGFR3 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HISTONE LYSINE METHYLTRANSFERASE; IMMUNOGLOBULIN HEAVY CHAIN; MESSENGER RNA; REPRESSOR PROTEIN; UNCLASSIFIED DRUG; WHSC1 PROTEIN, HUMAN;

ALLELES; CELL LINE; CHROMOSOME BANDING; CHROMOSOME PAINTING; CYCLINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; KARYOTYPING; MULTIPLE MYELOMA; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSLOCATION, GENETIC;

EID: 34248177968     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2006.12.009     Document Type: Article

References (13)

1. Bergsagel P.L., and Kuehl W.M. Chromosome translocations in multiple myeloma. Oncogene 20 (2001) 5611-5622
2. Kuehl W.M., and Bergsagel P.L. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2 (2002) 175-187
3. Magrangeas F., Cormier M.L., Descamps G., Gouy N., Lode L., Mellerin M.P., Harousseau J.L., Bataille R., Minvielle S., and Avet-Loiseau H. Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. Blood 103 (2004) 3869-3875
4. Ross F.M., Ibrahim A.H., Vilain-Holmes A., Winfield M.O., Chiecchio L., Protheroe R.K., Strike P., Gunasekera J.L., Jones A., Harrison C.J., Morgan G.J., and Cross N.C. Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia 19 (2005) 1634-1642
5. Eton O., Scheinberg D.A., and Houghton A.N. Establishment and characterization of two human myeloma cell lines secreting kappa light chains. Leukemia 3 (1989) 729-735
6. Martin-Subero J.I., Harder L., Gesk S., Schlegelberger B., Grote W., Martinez-Climent J.A., Dyer M.J., Novo F.J., Calasanz M.J., and Siebert R. Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. Int J Cancer 98 (2002) 470-474
7. van der Velden V.H., Hochhaus A., Cazzaniga G., Szczepanski T., Gabert J., and van Dongen J.J. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 17 (2003) 1013-1034
8. Chesi M., Bergsagel P.L., Brents L.A., Smith C.M., Gerhard D.S., and Kuehl W.M. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88 (1996) 674-681
9. Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., Kuehl W.M., and Bergsagel P.L. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 97 (2001) 729-736
10. Schmitz R., Renne C., Rosenquist R., Tinguely M., Distler V., Menestrina F., Lestani M., Stankovic T., Austen B., Brauninger A., Hansmann M.L., and Kuppers R. Insights into the multistep transformation process of lymphomas: IgH-associated translocations and tumor suppressor gene mutations in clonally related composite Hodgkin's and non-Hodgkin's lymphomas. Leukemia 19 (2005) 1452-1458
11. Guikema J.E., Fenton J.A., de Boer C., Kleiverda K., Brink A.A., Raap A.K., Estrov Z., Schuuring E., and Kluin P.M. Complex biallelic IGH rearrangements in IgM-expressing Z-138 cell line: involvement of downstream immunoglobulin class switch recombination. Genes Chromosomes Cancer 42 (2005) 164-169
12. Gertz M.A., Lacy M.Q., Dispenzieri A., Greipp P.R., Litzow M.R., Henderson K.J., Van Wier S.A., Ahmann G.J., and Fonseca R. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 106 (2005) 2837-2840
13. Bergsagel P.L., Kuehl W.M., Zhan F., Sawyer J., Barlogie B., and Shaughnessy Jr. J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106 (2005) 296-303